With novel HER2 antibody-drug conjugate (ADC) drugs showing survival benefit in HER2-positive, low-expressing patients with advanced and inoperable locally advanced breast cancer, whether male breast cancer could benefit from ADC-based drugs deserves further investigation. Here, ERBB2 is linked to breast cancer.